Roche Holding AG Stock
Your prediction
Roche Holding AG Stock
The price for the Roche Holding AG stock decreased slightly today. Compared to yesterday there is a change of -€3.800 (-0.960%).
Pros and Cons of Roche Holding AG in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Roche Holding AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Roche Holding AG | -0.960% | -0.303% | 6.814% | 43.324% | 8.636% | 60.569% | 60.569% |
| Beximco Pharmaceuticals Ltd. GDR | 0.000% | 0.971% | 10.638% | 0.000% | 16.071% | 4.418% | -45.833% |
| SELLAS Life Sciences Group Inc | 0.000% | -0.485% | -8.482% | 644.913% | 261.552% | 627.983% | 21.590% |
| Eledon Pharmaceuticals Inc. | 0.630% | 6.757% | -9.714% | 38.596% | 146.875% | 184.685% | -42.545% |
Comments
News
Seer Q2 Earnings Call Highlights
Key Points
- Interested in Seer, Inc.? Here are five stocks we like better.
- Seer’s second-quarter revenue fell year over year to $3.1 million from $4.1 million, pressured by academic and
Lineage Cell Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Lineage Cell Therapeutics, Inc.? Here are five stocks we like better.
- Pipeline progress: Lineage advanced preclinical programs in corneal disease, Type 1 diabetes and
Tandem Diabetes Care Q2 Earnings Call Highlights
Key Points
- Interested in Tandem Diabetes Care, Inc.? Here are five stocks we like better.
- Record second-quarter performance: Worldwide sales rose 6% year over year to $255 million, while pump